Injectable Unit Raising Funds In Ankleshwar
About Business
They are into manufacturing of leuprolide depot injection, octreotide injection, Tenecteplase acetate injection, liposomal amphotericin B, Propofol, Morphine, Fentanyl, Pethidine, Tramadol, Diazepam, and about 150 more.
Clientele type
They export majority of their products to countries like Malawi, Comoros, Mozambique, Rwanda, Angola, Cameroon, Venezuela, Papua New Guinea, Oman, Bhutan, Lebanon, Myanmar, Kyrgyzstan, Swaziland, and UAE.
Premises
OWNED
Premise Size: 3500 Sq Mtr
Market Value (in INR): 8.75 Cr
Plant Approvals: Uganda, Ethiopia, Kenya, DR Congo, Ghana, Nigeria, Peru, Philippines, Sri Lanka, Uzbekistan, and Yemen. Upcoming Audits: Libya, Iraq, Hungary (Application No.-51431/2023), Botswana, Thailand, and Nepal. Exporting to direct/ merchant: Malawi, Comoros, Mozambique, Rwanda, Angola, Cameroon, Venezuela, Papua New Guinea, Oman, Bhutan, Lebanon, Myanmar, Kyrgyzstan, Swaziland, and UAE. Products under registration: Pakistan, Magnolia (product registered waiting for PO), Dominican Republic, Guatemala, Honduras, Kazakhstan, Nicaragua, Panama, Vietnam, Azerbaijan, Ecuador, El Salvador, Gabon, Cambodia, and Georgia. Under Discussion: Russia, Bahrain, and Jordan.
Asking Price Includes
The terms of the transaction will be discussed with potential investors.
Asking Price
INR 10.00 Cr
Minimum ticket size
INR 10.00 Cr
Reason
The founders are seeking a Strategic Investor who can help them grow their business.
More Details
Their turnover is predominantly derived from their Ampoule line, accounting for 98% of current revenues. With the vial line now operational, they anticipate a revenue increase exceeding 100% in the next fiscal year, as evidenced by their pre-booked orders with advances received. Their product development is focused on niche molecules, including leuprolide depot injection, octreotide injection, Tenecteplase acetate injection, liposomal amphotericin B, Propofol, and a range of nanoparticle-based formulations currently in their pipeline. They have space to put one Lyo and one PFS line now working on the Biosimilar filling line (28D). Also studying bulk biosimilar production both mammalian and microbial.
Keywords
Business Tags
₹10 to ₹200 Cr
Complete Investment Banking Solution in 120 Days
Seamless Fundraising/M&A transactions
Start your growth journey with our 25+ Years of Experienced Professional Team.
Contact IBGrid Team